Analysts Set Clearside Biomedical, Inc. (NASDAQ:CLSD) Price Target at $6.00

Shares of Clearside Biomedical, Inc. (NASDAQ:CLSD – Get Rating) have been assigned an average rating of “Moderate Buy” from the six brokerages that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $6.00.

A number of equities research analysts recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and issued a $6.00 price objective on shares of Clearside Biomedical in a report on Friday, March 10th. Needham & Company LLC reduced their target price on shares of Clearside Biomedical from $5.00 to $4.00 and set a “buy” rating for the company in a research note on Friday, March 10th. StockNews.com initiated coverage on shares of Clearside Biomedical in a research note on Thursday. They issued a “hold” rating for the company. Finally, JMP Securities reduced their target price on shares of Clearside Biomedical from $7.00 to $6.00 and set a “market outperform” rating for the company in a research note on Friday, March 10th.

Insider Transactions at Clearside Biomedical

In other news, CEO George M. Lasezkay sold 20,030 shares of the firm’s stock in a transaction that occurred on Thursday, January 19th. The shares were sold at an average price of $1.46, for a total transaction of $29,243.80. Following the completion of the sale, the chief executive officer now owns 484,577 shares of the company’s stock, valued at $707,482.42. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Over the last 90 days, insiders sold 49,930 shares of company stock valued at $73,943. Corporate insiders own 12.00% of the company’s stock.

Institutional Trading of Clearside Biomedical

Hedge funds have recently modified their holdings of the stock. Balyasny Asset Management LLC bought a new stake in shares of Clearside Biomedical during the third quarter valued at approximately $25,000. JPMorgan Chase & Co. boosted its stake in Clearside Biomedical by 100.6% in the second quarter. JPMorgan Chase & Co. now owns 18,161 shares of the company’s stock valued at $27,000 after acquiring an additional 9,109 shares during the last quarter. Mackenzie Financial Corp bought a new position in Clearside Biomedical in the first quarter valued at approximately $27,000. Newman Dignan & Sheerar Inc. bought a new position in Clearside Biomedical in the third quarter valued at approximately $31,000. Finally, Banque Cantonale Vaudoise bought a new position in Clearside Biomedical in the fourth quarter valued at approximately $45,000. 20.07% of the stock is owned by institutional investors.

Clearside Biomedical Stock Up 8.4 %

Shares of NASDAQ:CLSD opened at $1.04 on Tuesday. The company’s fifty day moving average is $1.35 and its two-hundred day moving average is $1.27. Clearside Biomedical has a 12-month low of $0.93 and a 12-month high of $2.85. The company has a market cap of $63.81 million, a P/E ratio of -1.89 and a beta of 1.95.

Clearside Biomedical Company Profile

(Get Rating)

Clearside Biomedical, Inc is a biopharmaceutical company, which delivers therapies to the back of the eye through the suprachoroidal space. Its pipeline include CLS-AX, Integrin Inhibitor, and gene therapy. The company was founded by Samir Kumar Patel, Vladimir Zarnitsyn, Mark Prausnitz, Daniel H. White, and Henry F.